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Preterm Birth and the Controversy Over Universal Cervical
Length Screenings
Preterm birth (PTB), defined as birth
before 37 weeks gestation, is a major
population health problem. It is the
number one cause of neonatal morbidity
and mortality in developed countries-bearing significant societal healthcare
costs due to short-term consequences and
complications.1 It is a source of concern
for policymakers that PTB accounts for
12% of all births in the United States, a
higher rate than other developed nations.2
PTB preventative strategies include
transvaginal ultrasound (TVU) screening
and progesterone administration.3
Though the exact mechanism of action
of progesterone is not clear, it is thought
to provide an anti-inflammatory effect
and counteract the local decrease in
progesterone levels to decrease the
likelihood of PTB.
In 2012, the Society for MaternalFetal Medicine (SMFM) published
recommendations and the American
College of Obstetricians and
Gynecologists (ACOG) published
an opinion statement relevant to
progesterone to reduce PTB.4,5 Though a
number of studies were cited, evidence
is largely supported by two large trials
that found vaginal progesterone reduced
PTB compared to placebo. In 2007,
Fonseca et al. found that a vaginal
progesterone suppository (200mg each
night) reduced spontaneous PTB by 44%
(19% vs. 34% in the placebo group).6
The PREGNANT trial (The Effect of
Vaginal Progesterone Administration
in the Prevention of Preterm Birth in

Women With a Short Cervix), a more
recent randomized multi-center trial,
demonstrated the efficacy and safety of
a vaginal progesterone gel (90mg daily)
in reducing PTB risk and associated
neonatal complications. Results indicated
that the vaginal progesterone gel was
associated with a 45% reduction in
PTB before 33 weeks (9% treatment vs.
16% control) and was associated with a
43% significant reduction in composite
neonatal morbidity and mortality (8%
treatment vs. 14% control).7
The evolving evidence regarding
progesterone has stimulated controversy
as to whether all pregnant women should
receive a TVU screening to detect
short cervix (i.e., universal screening),
as opposed to screening only women
determined by their physician to be at
high risk for PTB. Since high risk is
typically defined based on history of
prior PTB, screening only these women
would leave out two major cohorts of
the pregnant population: 1) those who
are pregnant for the first time and have
a short cervix, and 2) those who have a
short cervix despite history of full-term
pregnancies. Proponents of universal
screening argue that it makes sense to
support this strategy since evidence
supports the benefit of progesterone in
women found to have short cervix.4 On
the other hand, opponents of universal
screening contend that: 1) there is a
lack of efficacy data specifically on the
strategy of universal TVU screening
followed by vaginal progesterone; 2) the

implementation of proper TVU screening
technique is required in order to ensure
accurate results; 3) certain geographic
areas lack sufficient availability of
TVU screening; 4) in certain women,
short cervix can be identified without
TVU; and 5) there is the possibility of
differing results when TVU screening
is completed in practice versus within a
clinical trial.4 SMFM recommendations
state that, though there is currently
insufficient evidence to support universal
screening, it is a reasonable practice for
individual physicians to choose.
In summary, while many clinicians
currently support a strategy of universal
TVU screening followed by progesterone
in women detected to have short
cervix, this remains an acceptable
but controversial practice. Until more
evidence is available, the issue will
persist as a topic of clinical debate. 
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